

STATUS OF THE CLAIMS

1-15 (Cancelled)

16. (Original) A method of protecting ocular neural tissue from damage caused by photodynamic therapy (PDT) comprising delivering to a patient's ocular neural tissue an amount of a neuroprotectant compound effective to protect a plurality of ocular neurons from cell death as compared to ocular neuron cell death observed in the absence of the administration of said neuroprotectant.

17. (Original) The method of claim 16 wherein said neuroprotectant compound is selected from the group consisting of NGF, PEDF, CNTF, BDNF, brimonidine and memantine.

18. (Original) The method of claim 16 wherein said neuroprotectant compound is administered at a time sufficiently before said PDT treatment to permit localization within ocular tissue prior to said treatment.

19. (Original) The method of claim 16 wherein said neuroprotectant compound is administered intravenously.

20. (Original) The method of claim 16 wherein said neuroprotectant compound is administered through intraocular injection.

21. (Currently Amended) The method of claim ~~14~~ 16 wherein said neuroprotectant compound is administered by subretinal injection.

22. (Currently Amended) The method of claim ~~14~~ 16 wherein said neuroprotectant compound is administered by intravitreal injection.

23-29 (Cancelled)

30. (Currently amended) The method of any of the preceding claims 16-~~29~~ 22 wherein said composition also comprises an therapeutically effective amount of a antiangiogenic compound.

31-38 (Cancelled)